UW Medicine Announces New Gene Therapy Research for Duchenne Muscular Dystrophy
For those who suffer from Duchenne muscular dystrophy (DMD), a novel gene therapy holds promise for both stopping muscle loss and maybe restoring the...
INS1201 Gene Therapy Phase 1 Clinical Trial Begins
Insmed was announced on the page published on ClinicalTrials.gov with the ID NCT06817382 that the phase 1 trials of INS1201 gene therapy developed for...
Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial (SRD-001) for Duchenne Muscular Dystrophy Associated Cardiomyopathy
Medera a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, and its clinical development division Sardocor, together with the University...
BBM-D101 Gene Therapy Phase 1/2 Clinical Trial Begins
Belief BioMed (BBM), headquartered in China, is a global innovative biotechnology company integrating the development, manufacturing and clinical application of gene therapy products. It...
RGX-202 Gene Therapy Phase 3 Clinical Trial Begins
RGX-202, one of the alternative gene therapy candidates developed for Duchenne Muscular Dystrophy, continues to accept applications from candidate participants for phase 3 clinical...